UCB SA (VIE:UCB)

Austria · Delayed Price · Currency is EUR

262.70

+14.80 (5.97%)

Last updated: Mar 5, 2026, 9:05 AM CET

46.35% (1Y)

Market Cap	50.08B
Revenue (ttm)	7.74B
Net Income (ttm)	1.56B
Shares Out	n/a
EPS (ttm)	8.03
PE Ratio	32.15
Forward PE	24.49
Dividend	0.97 (0.39%)
Ex-Dividend Date	Apr 25, 2025

Volume	n/a
Average Volume	26
Open	255.50
Previous Close	247.90
Day's Range	255.50 - 262.70
52-Week Range	131.70 - 288.60
Beta	n/a
RSI	34.86
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1925

Employees 9,765

Stock Exchange Vienna Stock Exchange

Ticker Symbol UCB

Full Company Profile

Financial Performance

In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.

Financial Statements

News

Belgium's UCB in autoimmune drug deal with Antengene

Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated ‌technology, paying $60 million up front and over $1.1 billio...

1 day ago - Reuters

UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ...

UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments Propel Future Prospects

2 days ago - GuruFocus

Full Year 2025 Ucb SA Earnings Call Transcript

2 days ago - GuruFocus

Best Income Stocks to Buy for March 2nd

CZNC, UCB and CRI made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 2, 2026.

2 days ago - Nasdaq

UCB SA (UCBJY) Q4 2025 Earnings Call Transcript

5 days ago - Seeking Alpha

UCB SA 2025 Q4 - Results - Earnings Call Presentation

2026-02-27. The following slide deck was published by UCB SA in conjunction with their 2025 Q4 earnings call.

5 days ago - Seeking Alpha

UCB SA Non-GAAP EPS of €9.99, revenue of €7.74B; introduces FY26 outlook

7 days ago - Seeking Alpha

Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight

14 days ago - GuruFocus

Best Income Stocks to Buy for February 12th

WTBA, UCB and RELX made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 12, 2026.

20 days ago - Nasdaq

Best Momentum Stocks to Buy for February 3rd

CX, UCB and TCBI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2026.

4 weeks ago - Nasdaq

Best Income Stocks to Buy for February 3rd

UCB, BCML and UBSI made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 3, 2026.

4 weeks ago - Nasdaq

UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

7 weeks ago - Seeking Alpha

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...

ARGX ARQT ISRG NVO VRTX

3 months ago - Seeking Alpha

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...

4 months ago - PRNewsWire